

ORIGINAL ARTICLE

Consistency of Quantitative Scores of Hypoglycemia Severity and Glycemic Lability and Comparison with Continuous Glucose Monitoring System Measures in Long-Standing Type 1 Diabetes

Peter A. Senior, MD, PhD,¹ Melena D. Bellin, MD,² Rodolfo Alejandro, MD,³ Jon W. Yankey, MS,⁴ William R. Clarke, PhD,⁴ Julie C. Qidwai, MS,⁴ Traci R. Schwieger, MA,⁴ Thomas L. Eggerman, MD, PhD,⁵ Mark A. Robien, MD, MPH,⁶ and Michael R. Rickels, MD, MS,⁷ for the Clinical Islet Transplantation Consortium*

Abstract

Background: In long-standing type 1 diabetes (T1D), loss of endogenous insulin secretion and glucose dysregulation can lead to severe hypoglycemia and associated complications. Here, we report the serial consistency and the correlation between different scores that characterize glucose dysregulation using self-monitoring of blood glucose (SMBG), in a cohort of T1D individuals being evaluated for transplant eligibility in Clinical Islet Transplantation Consortium trials.

Subjects and Methods: In total, 152 C-peptide–negative T1D subjects with at least one severe hypoglycemia episode in the prior year documented SMBG at enrollment and every 6 months until deemed ineligible or transplanted. SMBG was used to calculate the HYPO score, Lability Index (LI), and mean amplitude of glycemic excursion (MAGE). Additionally, a blinded continuous glucose monitoring system (CGMS) was worn for 72 h at enrollment and every 12 months.

Results: In this cohort, LI was the most consistent (intraclass correlation coefficient = 0.70) over time, followed by the HYPO score (0.51), with MAGE being the least consistent (0.36). Although MAGE and LI were highly correlated with each other, neither correlated with CGMS SD or glucose coefficient of variation (CV). Subjects spent a median of 97 min/day at <54 mg/dL using CGMS. The HYPO score correlated with CGMS time below 54 mg/dL and glucose CV.

Conclusions: The HYPO score and LI are more consistent than MAGE in patients with established T1D experiencing severe hypoglycemic events and may be especially useful both for identifying subjects experiencing the greatest difficulty in maintaining glycemic control and for longitudinal assessment of novel interventions.

¹Clinical Islet Transplant Program, Division of Endocrinology, University of Alberta, Edmonton, Alberta, Canada.

²Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.

³Diabetes Research Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.

⁴Clinical Trials Statistical and Data Management Center, Department of Biostatistics, University of Iowa, Iowa City, Iowa.

⁵Division of Diabetes, Endocrinology and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.

⁶Transplantation Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.

⁷Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

*The Clinical Islet Transplantation Consortium is a collaborative clinical research program funded by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Allergy and Infectious Diseases. Additional members of the Consortium who contributed to this study are listed in Supplementary Data (available online at www.liebertonline.com/dia).

This study is registered with ClinicalTrials.gov with clinical trial registration number NCT00434811.

Introduction

LONG-STANDING TYPE 1 DIABETES (T1D) is associated with loss of endogenous insulin secretion and defective glucose counterregulation that may result in “brittle” glucose dysregulation, including frequent hypoglycemia and glycemic lability. Recurrent hypoglycemia further impairs counterregulatory responses to and awareness of hypoglycemia, creating a cycle of more frequent, severe, and sometimes fatal hypoglycemia.¹ Hypoglycemia has well-characterized detrimental consequences² and causes 6–10% of T1D deaths.^{3,4} Although a validated assessment tool (Clarke score) exists for identifying patients with reduced awareness of hypoglycemia who are at increased risk of experiencing severe hypoglycemic episodes,^{5,6} not all patients with reduced hypoglycemia awareness experience problematic hypoglycemia. Because the Clarke score is based on a single recall questionnaire of experiences with hypoglycemia, additional assessment is required to identify those at greatest risk.

Glycemic lability, severe hypoglycemia, and reduced hypoglycemia awareness are interrelated manifestations of T1D-associated glucose dysregulation.^{7–9} Because of the morbidity and mortality associated with hypoglycemia and glucose dysregulation, various attempts have been made to develop practical and useful tools to quantify these phenomena, including the HYPO score,¹⁰ the Lability Index (LI),¹⁰ the mean amplitude of glycemic excursion (MAGE),¹¹ and continuous glucose monitoring system (CGMS) measures,¹² among others. However, relevant comparisons among these metrics have not yet been made, nor is it clear if such measures provide consistent results within the same patient if repeated over time.

Islet transplantation has emerged as a promising approach to β -cell replacement in highly selected subjects with long-standing T1D.¹³ Functioning islet grafts result in protection from severe hypoglycemia and stabilization of blood glucose levels¹⁰ that may be attributed to both restoration of endogenous insulin secretion and hormonal and symptom responses to hypoglycemia.^{14,15} The safety and efficacy of islet transplantation in long-standing T1D are being evaluated in a series of clinical trials under the auspices of the Clinical Islet Transplantation (CIT) Consortium, sponsored by the National Institutes of Health (www.isletstudy.org/). Because of the limited supply of donor organs and the risks associated with the transplant procedure and chronic immunosuppression, eligibility for the CIT trials is restricted to patients with severe hypoglycemic episodes and hypoglycemia unawareness or marked glycemic lability despite optimal medical therapy.

In the CIT Consortium trials, clinical history, self-monitoring of blood glucose (SMBG), and CGMS data were prospectively collected, and Clarke, HYPO, LI, and MAGE scores were calculated. (An overview of HYPO, LI, and MAGE scores is given in Supplementary Table S1).

Key criteria for transplantation under the CIT trials included at least one severe hypoglycemia episode in the past year and reduced awareness of hypoglycemia (Clarke score ≥ 4), as well as markedly problematic hypoglycemia or glycemic lability as determined by twice yearly calculation of HYPO score and LI from subjects' SMBG; additional assessments included MAGE measurements and yearly blinded CGMS. Although the HYPO score and LI were developed specifically for use in islet transplantation and have been

validated against clinical assessment and compared with the general T1D population,¹⁰ the serial consistency of these indices has not been evaluated to date. Using results for various measures of hypoglycemia and glucose lability obtained during eligibility evaluation and the pretransplant period for the CIT trials, this study specifically (1) examined the serial consistency of HYPO, LI, and MAGE scores obtained in this cohort, as assessed by the intraclass correlation coefficient (ICC), and (2) characterized the correlation between these three SMBG-based scores and measures of hypoglycemia and glycemic variability derived from CGMS recordings.

Subjects and Methods

Subjects

Subjects in this study were enrolled in six CIT islet-alone trials conducted at eight Consortium centers in North America. The trials enrolled C-peptide-negative T1D subjects between 18 and 65 years of age who had experienced at least one episode of severe hypoglycemia¹⁶ in the year prior to enrollment despite participation in intensive diabetes management. Intensive diabetes management was defined as SMBG at least three times daily with use of three or more daily injections of insulin or continuous subcutaneous insulin infusion therapy under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least three clinical evaluations during the year prior to enrollment. The inclusion and exclusion criteria and study end points are listed on the Web site ClinicalTrials.gov under clinical trial registration number NCT00434811. The study protocols were approved by each center's Institutional Review Board, and all subjects gave their written informed consent to participate.

The key glycemic inclusion criteria for CIT trials were as follows: HYPO score of $>1,047$ or LI of >433 , representing the 90th percentile from a general T1D cohort, thus identifying subjects with severe problems with hypoglycemia or glycemic lability, respectively.¹⁰ In addition, subjects with a composite of both HYPO score of >423 and LI of >329 , representing the 75th percentiles,¹⁰ were eligible if they also manifested reduced awareness of hypoglycemia that was indicated by a Clarke score of ≥ 4 .⁵ The Clarke surveys were administered at study visits by trained study coordinators.

Three hundred forty-one subjects provided informed consent to participate in the North American islet-alone CIT trials. Because this study's objectives are to characterize the HYPO, LI, and MAGE scores in subjects being evaluated for islet transplantation, all available calculations were used, even if a subject was eventually deemed ineligible for transplantation. Subjects were asked to complete SMBG every 6 months until they were deemed ineligible or received a transplant. Subjects were instructed to complete SMBG at least premeal and bedtime (four times daily), with additional 2-h postmeal checks (seven times daily) during at least 7 consecutive days of the 28-day recording period. Some of the subjects were deemed ineligible prior to submitting SMBG, such that 152 subjects who provided at least one suitable SMBG (at least 28 days of blood glucose readings within a 35-day period) are included in the analyses. Their baseline characteristics are presented in Table 1. There were no significant differences in baseline characteristics between the 152 subjects analyzed and the consented subjects who were not included in the analyses.

TABLE 1. BASELINE CHARACTERISTICS

| Characteristic | All consented (n = 341) | Complete HYPO/LI data (n = 143) | Complete MAGE data (n = 152) | Complete CGMS data (n = 75) |
|--------------------------|----------------------------|------------------------------------|---------------------------------|--------------------------------|
| Gender [n (%)] | | | | |
| Male | 111 (32.5) | 54 (37.8) | 57 (37.5) | 31 (41.3) |
| Female | 204 (59.8) | 89 (62.2) | 95 (62.5) | 44 (58.6) |
| Missing | 26 (7.62) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Age (years) | | | | |
| Mean | 44 | 45 | 45 | 44 |
| SD | 11.6 | 11.5 | 11.2 | 11.0 |
| Minimum–maximum | 18–65 | 19–65 | 19–65 | 19–63 |
| T1D duration (years) | | | | |
| Mean | 27 | 29 | 28 | 28 |
| SD | 11.6 | 11.5 | 11.7 | 12.1 |
| Minimum–maximum | 6–57 | 6–57 | 6–57 | 6–48 |
| Weight (kg) | | | | |
| Mean | 72.8 | 72.5 | 72.4 | 72.9 |
| SD | 12.7 | 12.7 | 12.6 | 12.1 |
| Minimum–maximum | 48–112 | 48–112 | 48–112 | 48–99 |
| BMI (kg/m ²) | | | | |
| Mean | 25.2 | 25.1 | 25.1 | 25.2 |
| SD | 3.07 | 2.98 | 3.00 | 2.98 |
| Minimum–maximum | 18.3–33.2 | 18.7–33.2 | 18.7–33.2 | 18.7–33.2 |
| Insulin dose (units/kg) | | | | |
| Mean | 0.52 | 0.51 | 0.52 | 0.51 |
| SD | 0.15 | 0.15 | 0.15 | 0.15 |
| Minimum–maximum | 0.17–1.00 | 0.17–0.86 | 0.17–0.86 | 0.18–0.86 |
| HbA1c (%) | | | | |
| Mean | 7.43 | 7.23 | 7.22 | 7.16 |
| SD | 1.13 | 1.05 | 1.04 | 1.14 |
| Minimum–maximum | 4.3–11.4 | 4.3–11.4 | 4.3–11.4 | 4.3–11.4 |
| Clarke score | | | | |
| Mean | 5.86 | 5.94 | 5.98 | 6.12 |
| SD | 1.15 | 1.09 | 1.10 | 0.99 |
| Minimum–maximum | 2–7 | 2–7 | 2–7 | 3–7 |

Baseline characteristics are shown of all subjects who provided consent and of those included for analysis based on complete HYPO score/Lability Index (LI) data, complete mean amplitude of glycemic excursion (MAGE) data, and complete continuous glucose monitoring system (CGMS) data.

BMI, body mass index; HbA1c, glycosylated hemoglobin; T1D, type 1 diabetes.

Determination of HYPO, LI, and MAGE scores

The methods for calculation of HYPO and LI scores and for calculation of the MAGE have been described previously.^{10,11} The calculation of the HYPO and LI scores requires that there are at least 28 days of capillary blood glucose tests within a 35-day period with at least four tests per day. For calculation of the MAGE, the SMBG must contain 2 consecutive days with at least seven capillary blood glucose tests on each day. It was not always possible to calculate all three scores from a single SMBG. In some cases, the data requirements were satisfied for calculation of both HYPO and LI scores but not MAGE, or vice versa.

Assessment of HYPO, LI, and MAGE consistency

To examine the serial consistency of HYPO, LI, and MAGE scores, data from all 152 subjects providing at least one suitable SMBG were analyzed; in total, 288 MAGE calculations were available for analyses of repeated assessments (Supplementary Fig. S1). Only 143 of these 152 subjects satisfied data requirements to calculate the HYPO and

LI scores; in total, 259 HYPO and LI calculations were available for analyses of repeated assessments (Supplementary Fig. S1).

Comparison of continuous glucose monitoring with HYPO, LI, and MAGE scores

In addition to collecting SMBG, subjects underwent blinded CGMS (iPro[®]; Medtronic, Northridge, CA) for 72 h every 12 months until they received a transplant or were deemed ineligible. The CGMS can provide detailed information about glycemia over several days with little additional work for the patient, but is limited by the shorter assessment period. For the analyses comparing the performance of HYPO, LI, and MAGE with CGMS data, only data from subjects for whom all three scores could be calculated from a single blood glucose record and who had an eligible CGMS recording of at least 48 h in duration performed prior to transplant were included. A single dataset at the visit just prior to transplant was included for each subject. Seventy-five subjects had suitable CGMS data and an SMBG containing




FIG. 1. Score consistency: serial consistency of pretransplant (or until deemed ineligible) scores for (A) HYPO score, (B) Liability Index (LI), and (C) mean amplitude of glycemic excursion (MAGE).

sufficient data to calculate HYPO, LI, and MAGE (Supplementary Fig. S1). CGMS data were missing for 62 subjects who otherwise had eligible SMBG due to subsequent protocol ineligibility ($n=38$), transplantation ($n=6$), CGMS malfunction ($n=7$), or other reason ($n=12$). Of the 75 subjects with suitable CGMS data, 51 (68%) used continuous subcutaneous insulin infusion therapy, including seven (9%) with real-time continuous glucose monitoring. No subjects switched treatment modality prior to transplant. The CGMS summary data generated by Medtronic proprietary software were entered into the trial database. The investigators were unable to access the raw sensor data.

Statistical methods

The serial consistencies of HYPO, LI and MAGE were evaluated using the ICC, which is computed as the ratio of the between-subject variance to the sum of the between-subject variance and the within-subject variance. This value ranges between 0.0 and 1.0 and is an estimate of the correlation between repeated observations on the same subject. The relationships among HYPO, LI, MAGE, and CGMS summary data were explored using Spearman's correlation coefficient. Specifically, HYPO, LI, and MAGE scores were compared against the proportion of time spent <54 mg/dL by CGMS as a measure of clinically significant hypoglycemia exposure,¹⁷ as well as against the CGMS SD and the CGMS coefficient of variation (CV) as measures of glucose variability.¹² Statistical significance was considered at $P < 0.05$ (two-tailed).

Results

HYPO, LI, and MAGE scores

Up to nine SMBG records, collected at 6-month intervals, were included per subject, with the median number being two. The mean number of daily blood glucose values recorded remained seven through five consecutive assessments for LI (Supplementary Table S2). The serial consistency of HYPO, LI, and MAGE data for each subject included in the analyses is illustrated in Figure 1. LI was the most consistent measure (ICC=0.70 [95% confidence interval, 0.59, 0.78]), followed by the HYPO score (ICC=0.51 [95% confidence interval, 0.36, 0.63]), whereas MAGE was the least consistent measure (ICC=0.36 [95% confidence interval, 0.21, 0.50]) (Supplementary Table S3).

The median (interquartile range) scores calculated from the blood glucose records were as follows: HYPO score, 1,419 (717–2,707); LI, 550 (397–712); and MAGE, 158 (123–201). The percentages of scores above inclusion criteria threshold were as follows: 63% of HYPO scores were $>1,047$; 72% of LI scores were >433 ; 76% had both HYPO and LI scores above the 75th percentile of overall T1D clinic patients; and 96% of Clarke scores were ≥ 4 (Fig. 2). Of the 143 subjects with complete HYPO score and LI data, key glycemic inclusion criteria for CIT trials were met by 94 subjects for the HYPO criterion ($>1,047$), 101 subjects for the LI criterion (>433), and 108 subjects for the composite criteria (HYPO score of >423 and LI of >329).

Comparison of SMBG-derived scores with CGMS

The CGMS summary data and HYPO, LI, and MAGE scores from the 75 subjects having CGMS data are presented

in Supplementary Table S4. The mean absolute difference for the CGMS data was $13 \pm 6\%$. The mean scores for HYPO, LI, and MAGE in this subset are not different from those of the whole sample described earlier. The mean time spent with blood glucose levels below 54 mg/dL was 1 h 37 min per day (with a range between 0 and 9 h 42 min per day). The mean time spent above 180 mg/dL was 12 h 13 min per day (with a range between 0 and 24 h per day).

The relationships between the SMBG derived scores and the CGMS summary data are shown in Table 2. The HYPO score was significantly correlated with both CGMS percentage of time spent <54 mg/dL ($r_s=0.57$, $P < 0.0001$) and with CGMS CV ($r_s=0.36$, $P=0.001$), but not with CGMS SD ($r_s=-0.06$, $P=0.6$). The relationships between HYPO score and CGMS percentage of time spent <54 mg/dL and with CGMS CV are shown in Supplementary Figure S2. Although correlated with each other ($r_s=0.56$, $P < 0.0001$), neither LI nor MAGE was correlated with CGMS SD ($r_s=0.16$ and 0.17, respectively; P =not significant for both) or with CGMS CV ($r_s=-0.10$ and -0.14 , respectively; P =not significant for both).

Discussion

The distribution of HYPO and LI scores, derived from 4-week SMBG, clearly demonstrate that the subjects enrolled in the CIT Consortium islet transplant trials represent a highly selected subset of individuals with T1D who had frequent, severe hypoglycemia and glycemic lability. In these subjects, the serial HYPO and LI scores were less variable upon repeat assessment than serial MAGE scores.

Although LI and MAGE provide quantitative measures of glucose variability and are closely correlated, LI was more consistent (i.e., less variable over time). The variability of repeated measures of MAGE, months apart, in this population where extreme glycemic variability is the norm is likely due to the short observation period. There is a greater chance that the 2-day period is atypical, compared with the 28-day evaluation period used to calculate LI. Although the SMBG requirements for LI (four tests per day for 28 days) may be more demanding than the seven tests per day on 2 consecutive days required for MAGE, the numbers of SMBG records (numbers are provided in Supplementary Fig. S1) that satisfied the criteria for the calculation of MAGE and LI were similar. In this population of patients with long-standing T1D, the use of LI to assess glycemic lability is both preferable and feasible. It is important to recognize that LI is affected by the frequency of SBGM such that increased frequency of monitoring will result in a higher LI. In our study, which required a minimum of four tests per day, the frequency of SMBG was consistent over time, with subjects testing, on average, seven times daily. Thus, the consistency of LI reported here likely depended on the consistency of frequent SMBG practiced in this population of patients with long-standing T1D.

The HYPO score comprises two components: first, a score calculated from the SMBG for each episode of hypoglycemia (glucose level of <54 mg/dL) is tallied over the 28-day observation period, where symptomatic episodes requiring third-party assistance receive a higher score; and second, a component based on historical recall of hypoglycemic events requiring assistance during the preceding 12 months.




FIG. 2. Scatter plot of log HYPO score and Lability Index (LI) calculated from the blood glucose record. The dotted line indicates the 90th percentile of the general type 1 diabetes population, and the solid line is the 75th percentile¹⁰; these are the thresholds used for eligibility determination in the Clinical Islet Transplantation trials.

TABLE 2. CORRELATIONS AMONG MEASURES

| | <i>LI score</i> | <i>MAGE score</i> | <i>CGMS % time <54 mg/dL</i> | <i>CGMS SD</i> | <i>CGMS CV</i> |
|---------------------------------|-----------------|-------------------|---------------------------------|----------------|----------------|
| HYPO score | | | | | |
| <i>r_s</i> | -0.0658 | -0.1534 | 0.5679 | -0.0611 | 0.3633 |
| <i>P</i> value | 0.5724 | 0.1856 | <0.0001 | 0.6022 | 0.0014 |
| <i>n</i> | 76 | 76 | 75 | 75 | 75 |
| LI score | | | | | |
| <i>r_s</i> | | 0.5594 | -0.1531 | 0.1620 | -0.0998 |
| <i>P</i> value | | <0.0001 | 0.1896 | 0.1648 | 0.3940 |
| <i>n</i> | | 76 | 75 | 75 | 75 |
| MAGE score | | | | | |
| <i>r_s</i> | | | -0.1755 | 0.1659 | -0.1444 |
| <i>P</i> value | | | 0.1320 | 0.1547 | 0.2162 |
| <i>n</i> | | | 75 | 75 | 75 |
| CGMS % time <54 mg/dL | | | | | |
| <i>r_s</i> | | | | 0.1859 | 0.7016 |
| <i>P</i> value | | | | 0.1102 | <0.0001 |
| <i>n</i> | | | | 75 | 75 |
| CGMS SD | | | | | |
| <i>r_s</i> | | | | | 0.5969 |
| <i>P</i> value | | | | | <0.0001 |
| <i>n</i> | | | | | 75 |

Spearman correlation coefficients (*r_s*) are shown for HYPO score, Lability Index (LI), mean amplitude of glycemic excursion (MAGE), and continuous glucose monitoring system (CGMS) summary data.

CV, coefficient of variation.

For subjects with the highest HYPO scores, the high score is generally driven by the historical component. Because HYPO scores were calculated every 6 months in this study, there was some overlap of the historical component between sequential measurements. Subjects having initial high HYPO scores due to historical events occurring more than 12 months earlier may have lower HYPO scores at subsequent assessments because those historical events no longer contribute to the current score. Thus, changes in the historical recall component in those with the highest scores may explain the greater variability of HYPO compared with LI.

The calculation of HYPO and LI is labor-intensive, both for the subject collecting the data and for those who have been trained to calculate the scores. Subjects not only are required to perform four blood glucose tests daily for 28 days, but must also record a description of the symptoms, circumstances, and treatment for each episode of hypoglycemia. Potentially, CGMS could provide a means to assess glycemic variability with minimal input from the individual being assessed and automated calculation of summary statistics. In this study, subjects were asked to wear the CGMS device for 3 days, but subjects with only 48 h of recordings, because of sensor dropout or early sensor removal, were included. Consequently, the period evaluated by CGMS was relatively short and, like MAGE, may be subject to sampling error because of the high levels of glucose variability in this population.

Nevertheless, the HYPO score was correlated with both the proportion of time spent below 54 mg/dL and with the CGMS CV, but not with CGMS SD. This suggests that the

risk of hypoglycemia associated with glucose variability is influenced by mean glucose levels (both of which are reflected by CGMS CV, whereas only variance is reflected by CGMS SD). CGMS has been a powerful tool to identify unrecognized, subclinical hypoglycemia. Subclinical hypoglycemia impairs glucose counterregulatory mechanisms, driving hypoglycemia-associated autonomic failure and impaired hypoglycemic awareness, which are associated with increased risk of severe hypoglycemic events.^{1,18} In a subgroup of 19 subjects meeting the CIT trial glycemic inclusion criteria who underwent paired hypoglycemic and euglycemic clamps to determine glycemic thresholds for glucose counterregulation (measured as endogenous glucose production) and autonomic symptom generation (M.R.R., unpublished data), 15 subjects had absent glucose counterregulation, and 14 had absent symptom awareness, using the previously defined glycemic threshold for each response as <54 mg/dL.⁶ Thus, the HYPO score and LI, as defined as inclusion criteria for the CIT trials, do indeed identify individuals with compromised physiologic defenses against the development of hypoglycemia.

It was surprising that there was no correlation between CGMS SD or CGMS CV and either LI or MAGE, even though LI and MAGE correlated with each other. Although CGMS SD provides some representation of glycemic variability, it does not capture the same information as LI or MAGE. SD simply describes the arithmetic variance in values around the mean, irrespective of their sequence, whereas the variability captured by LI and MAGE reflects clinically relevant swings in blood glucose level from high to low in terms of either magnitude (MAGE) or both magnitude and frequency (LI). Thus a sequence of SMBG values (75, 120, 160, 200, 250, 280 mg/dL) with a high SD may not demonstrate glycemic lability when compared with a series of labile glucose values (40, 120, 40, 160, 55, 120 mg/dL) that has a smaller SD. Glucose SD is most useful when restricted to a defined time period (e.g., fasting plasma glucose levels) to describe interday variations, but may not be the best metric to quantify variability over a period of days or weeks.

Summary data produced by software from commercially available CGMS devices are predominantly designed for clinical use. Although CGMS summary data provide complementary information, they do not appear to be sufficiently detailed to be used as a replacement for HYPO score and LI calculated from SMBG to fully assess hypoglycemia and glycemic lability, respectively. Although time spent in the hypoglycemic range and CGMS CV both correlated with HYPO score, CGMS does not directly assess hypoglycemia unawareness and may not fully assess risk for episodes of severe hypoglycemia.¹⁹ Glycemic lability might be more fully assessed if CGMS devices were used over a longer period of time, which may now be feasible because current CGMS sensors can be worn for up to 7 days.

We used the software-generated CGMS SD and CGMS CV available at the start of the CIT trials as measures of glycemic variability for this analysis as there is no consensus for how best to use CGMS to quantify glucose variability.²⁰ If we had access to raw sensor data, it would have been possible to calculate other CGMS summary measures, which include a time component (e.g., continuous overlapping net glycemic action)²¹ or glucose rate of change SD²²) and might ultimately relate better to glycemic lability as captured by the LI.

In conclusion, this is the first report to compare the performance of various tools to quantify hypoglycemia severity and glycemic lability in patients with long-standing T1D. Although labor-intensive, the HYPO score and LI appear to be reliable assessments for identifying subjects experiencing severe problems with hypoglycemia and extreme glycemic lability. MAGE is a less reproducible measure of glycemic variability than LI and does not appear to provide additional information. Currently, summary data from short periods of CGMS provide relatively rapid assessments but do not appear to provide sufficiently robust data to replace SMBG scores in fully characterizing severe hypoglycemia and glucose lability. The HYPO score and LI thus appear to be useful tools that may be valuable as surrogate end points in trials of treatments and technologies designed to reduce hypoglycemia and/or glycemic lability, including islet transplantation.

Acknowledgments

This work was performed as a project of the CIT Consortium, a collaborative clinical research program headquartered at the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of Allergy and Infectious Diseases and supported by U.S. Public Health Services research grants U01 DK070430 (to the University of Pennsylvania), U01 DK070431 (to the University of Iowa), U01 DK070460 (to the University of Miami), U01DK085531 (to the University of California San Francisco), U01 AI065191 (to the University of Alberta), U01 AI065193 (to the University of Minnesota), U01AI089316 (to Northwestern University), U01 AI089317 (to Emory University), and U01 5U01DK070431-10 (to the University of Illinois at Chicago), as well as by Clinical & Translational Science Awards UL1 TR000003 (to the University of Pennsylvania), UL1 TR000004 (to the University of California San Francisco), UL1 TR000050 (to the University of Illinois at Chicago), UL1 TR000114 (to the University of Minnesota), UL1 TR000150 (to Northwestern University), UL1 TR000454 (to Emory University), and UL1 TR000460 (to the University of Miami) and also by grant RO1 DK091331 (to M.R.R.). We would like to thank the referring endocrinologists and diabetologists and the industry sponsor, LifeScan Inc./Johnson & Johnson Co., for contributing their products to the CIT trials.

Author Disclosure Statement

P.A.S. has received consultancy fees from Medtronic, Canada. M.D.B., R.A., J.W.Y., W.R.C., J.C.Q., T.R.S., T.L.E., M.A.R., and M.R.R. declare no competing financial interests exist.

References

1. Cryer PE: Mechanisms of hypoglycemia-associated autonomic failure in diabetes. *N Engl J Med* 2013;369:362–372.
2. Gold AE, MacLeod KM, Deary IJ, et al.: Hypoglycemia-induced cognitive dysfunction in diabetes mellitus: effect of hypoglycemia unawareness. *Physiol Behav* 1995;58:501–511.
3. Feltbower RG, Bodansky HJ, Patterson CC, et al.: Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults. *Diabetes Care* 2008;31:922–926.

4. Skrivarhaug T, Bangstad HJ, Stene LC, et al.: Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. *Diabetologia* 2006;49:298–305.
5. Clarke W, Cox D, Gonder-Frederick L, et al.: Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. *Diabetes Care* 1995;18:517–522.
6. Janssen MM, Snoek FJ, Heine RJ: Assessing impaired hypoglycemia awareness in type 1 diabetes: agreement of self-report but not of field study data with the autonomic symptom threshold during experimental hypoglycemia. *Diabetes Care* 2000;23:529–532.
7. Cox DJ, Kovatchev BP, Julian DM, et al.: Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. *J Clin Endocrinol Metab* 1994;79:1659–1662.
8. Pedersen-Bjergaard U, Pramming S, Heller SR, et al.: Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. *Diabetes Metab Res Rev* 2004;20:479–486.
9. Kilpatrick ES, Rigby AS, Good K, et al.: Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. *Diabetologia* 2007;50:2553–2561.
10. Ryan E, Shandro T, Green K, et al.: Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. *Diabetes* 2004;53:955–962.
11. Service FJ, Molnar GD, Rosevear JW, et al.: Mean amplitude of glycemic excursions, a measure of diabetic instability. *Diabetes* 1970;19:644–655.
12. Rodbard D: Hypo- and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. *Diabetes Technol Ther* 2012;14:868–876.
13. Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. *Diabetes Care* 2012;35:1436–1445.
14. Rickels MR, Schutta MH, Mueller R, et al.: Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. *Diabetes* 2005;54:3205–3211.
15. Rickels MR, Schutta MH, Mueller R, et al.: Glycemic thresholds for activation of counterregulatory hormone and symptom responses in islet transplant recipients. *J Clin Endocrinol Metab* 2007;92:873–879.
16. DCCT Research Group: Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. *Am J Med* 1991;90:450–459.
17. UK Hypoglycaemia Study Group: Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. *Diabetologia* 2007;50:1140–1147.
18. Cryer PE: Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. *Diabetes* 2005;54:3592–3601.
19. Choudhary P, Geddes J, Freeman JV, et al.: Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring. *Diabet Med* 2010;27:666–672.
20. Bergenstal RM, Ahmann AJ, Bailey T, et al.: Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). *Diabetes Technol Ther* 2013;15:198–211.
21. McDonnell CM, Donath SM, Vidmar SI, et al.: A novel approach to continuous glucose analysis utilizing glycemic variation. *Diabetes Technol Ther* 2005;7:253–263.
22. Kovatchev BP, Clarke WL, Breton M, et al.: Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical applications. *Diabetes Technol Ther* 2005;7:849–862.

Address correspondence to:

Peter A. Senior, MD, PhD

University of Alberta

#2000 College Plaza

8215 112 Street

Edmonton, AB, T6G2C8, Canada

E-mail: peters@islet.ca

or

Michael R. Rickels, MD, MS

12-134 Smilow Center for Translational Research

University of Pennsylvania

3400 Civic Center Boulevard

Philadelphia, PA 19104

E-mail: rickels@mail.med.upenn.edu